MLEC — Moolec Science S.A.

Moolec Science Q4 2024 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue Growth: Normalized revenues increased to $5.8 million in FY2024 from approximately $1 million in FY2023, driven by the consolidation of the soy product ingredient business.
• Cost of Sales: Rose to $4.5 million in FY2024, aligning with revenue growth.
• Expenses: SG&A and R&D expenses increased to $9.3 million from $6.2 million in FY2023, primarily due to non-cash items and consolidation costs.
• Cash Position: Cash reserves stood at approximately $5.4 million at the end of Q4 2024, supplemented by a convertible note to BIOX for the purchase of HB4 soybeans, covering projected raw material needs until December 2025.

2. Strategic Updates and Business Highlights

• Regulatory Achievements: Received USDA approval for the Piggy Sooy product, marking a significant milestone as the first company in the industry to achieve such approval.
• Product Development: Successfully established a molecular biology lab in Texas, enhancing R&D capabilities and cost efficiency.
• Commercialization Efforts: Initiated field trials for Piggy Sooy in multiple states and began planting Glaso seeds, with an offtake agreement signed with a major global CPG company for Glaso, targeting the pet food market.
• R&D Collaboration: Entered into a partnership with Bunge to develop safflower varieties, enhancing productivity and opening new business opportunities.

3. Forward Guidance and Outlook

• FY2025 Expectations: Anticipate the commercialization of Glaso, contributing approximately 15% to total revenues. The company expects gradual revenue growth from the soy protein ingredient business, projecting around $6 million in FY2025.
• Operational Focus: Plans to optimize production processes, enhance seed inventory, and continue pursuing regulatory approvals for new products.
• Market Engagement: Aiming to expand visibility through industry shows and marketing efforts to drive awareness and adoption of PMF products.

4. Bad News, Challenges, or Points of Concern

• Increased Expenses: Rising operational costs due to consolidation and non-cash items may pressure margins.
• Cash Utilization: Increased cash used in operating activities, which could raise concerns about financial sustainability in the near term.
• Regulatory Risks: While progress has been made, ongoing regulatory approvals for new products remain a critical path that could impact timelines.
• Market Competition: The company faces competition from established players in the food and supplement markets, which may affect pricing and market penetration.

5. Notable Q&A Insights

• Offtake Agreement Details: The agreement with a major CPG company is a three-year contract focused on pet food, with expectations of significant revenue contributions in the coming years.
• Commercialization Pipeline: Discussions with potential customers for Glaso are ongoing, with confidence expressed in selling the entire production for the current campaign.
• Market Awareness: Management emphasized the importance of educating R&D departments about their technology, indicating a focused B2B strategy rather than broad consumer marketing.
• Future Growth Potential: The partnership with Bunge is seen as a strategic move to enhance product offerings and market reach, with expectations for increased collaboration on both safflower and soybean products.

This summary encapsulates the key financial metrics, strategic initiatives, forward-looking statements, and potential challenges faced by Moolec Science as discussed in the Q4 2024 earnings call.